Is CG Oncology’s IPO a benchmark for a better year in public offerings? 

NEW YORK — CG Oncology rang the Nasdaq opening bell on Thursday morning, marking a rare sight for biotechs over the past two years as the volume of initial public offerings shrank from nearly 100 in 2021 to about a dozen in 2023.

Depending on how the market reacts to…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks